Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Gene Variant Descriptions||KDR (VEGFR2) positive indicates the presence of the KDR gene, mRNA, and/or protein.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KDR positive||Advanced Solid Tumor||predicted - sensitive||Tanibirumab||Phase I||Actionable||In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360).||28391576|
|KDR positive||pancreatic cancer||sensitive||TAS-115||Preclinical||Actionable||In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932).||24140932|
|KDR positive||melanoma||predicted - sensitive||Anti-VEGFR2 CAR CD8 lymphocytes||Preclinical||Actionable||In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).||23633494|
|KDR positive||Advanced Solid Tumor||predicted - sensitive||Anti-VEGFR2 CAR CD8 lymphocytes||Preclinical||Actionable||In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).||20978347|
|KDR pos RET C634W||thyroid gland medullary carcinoma||predicted - sensitive||Motesanib Diphosphate||Preclinical - Cell line xenograft||Actionable||In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).||21422803|